HealthShares Metabolic Endocrine Disorders ETF (HHM)
-
Quote & Analysis
-
Forum
Loading...
Symbols:
HHM Forum Topics
- All Comments on HHM
- General Discussion on HHM
- Struggling ETFs [view article]
- Watch Expenses & Spreads For HealthShares, PowerShares, WisdomTree ETFs [view article]
- Interview With X-Shares Founder & Chairman, Jeffrey Feldman [view article]
- ETF Fund Revenues: A View from the Bottom [view article]
- Healthcare, Pharma and Biotech ETFs [view article]
- Are HealthShares ETFs Too Specialized? [view article]
- Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
- Sixty-Seven ETF Filings For a New Year [view article]
Recent HHM Articles
- Struggling ETFs
- ETF Fund Revenues: A View from the Bottom
- Is the ETF Universe Beginning to Shrink?
- HealthShares ETFs: Diagnostics Appears a Winner
- ETF Update: XLF Fire Sale, Sayonara Yen Carry Trade?, Healthy Healthcare ETFs, Pinch Pennies With ETFs
- Interview With X-Shares Founder & Chairman, Jeffrey Feldman
- Watch Expenses & Spreads For HealthShares, PowerShares, WisdomTree ETFs
- Are HealthShares ETFs Too Specialized?
- Healthcare, Pharma and Biotech ETFs
- Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
loading ...
ocks
Struggling ETFs [view article]
I think its unfair to list NETS etfs in this list even though they have very few assets.NETS launched a whole bunch of these country specific etfs like DAX for Germany recently. So it may take some time before they grow. What do other readers think? ReplyStruggling ETFs [view article]
also etns may be easier to create by issuer than etfsif a demand appears
the issue is whether ubs feels it pays to have resources devoted to a 5 mln indexed certificate of deposit (uag)
plus timing, nets may take some time to take off Reply
Struggling ETFs [view article]
in second tableisn't turnover more relevant than volume?
ok brk is rather a mouthfull
but on this scale een seems twice as illiquid as ifeu, although ranked otherwise Reply
Tiedeman
ETF Fund Revenues: A View from the Bottom [view article]
Nice data! Thanks! ReplyEditors
General Discussion on HHM
Is this a buy or a sell? ReplyHealthcare, Pharma and Biotech ETFs [view article]
The Matt Hougan article on theme ETF expenses is helpful -- thanks for the pointer. He's right -- makes you want to buy the stocks of the ETF firms more than the ETFs themselves. ReplyWatch Expenses & Spreads For HealthShares, PowerShares, WisdomTree ETFs [view article]
Very interesting article. Spreads and expenses are rising on the new specialty ETFs, while the broad index ETFs are getting cheaper due to competition (eg. the new bond ETFs from State Street and Vanguard).Perhaps investors who want to play themes, (like healthcare subsectors and "green" investing) just don't care about expenses. If that's correct, the specialty ETF providers will have very profitable businesses. Reply
Brochstein
Are HealthShares ETFs Too Specialized? [view article]
When I first learned of the HealthShares concept, I was rather excited. I had always found that there were very few healthcare funds that invested in smaller companies (the few that do are actively managed). Any sort of passive vehicle was heavily weighted by Big Pharma, as are most of the actively managed ones.Well, these guys have gone WAY too far. This is far too specialized. Any investors in these funds had better be prepared to be long-term holders, as the liquidity will probably never be very good. Perhaps going as a mutual fund might have made more sense. Reply
Editors
Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
Having hit the time limit on this interactive Q&A, we're now closing it to further questions.Many thanks to Mr Feldman for his participation, and to Seeking Alpha's readers for their questions and comments. Reply
Jackson
Healthcare, Pharma and Biotech ETFs [view article]
Have we missed out any ETFs here? Or any Seeking Alpha articles that are important to understanding them? If so, please leave a comment and let us know! ReplyInteractive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
Thanks, Tom. No, I have no formal training in either medicine or healthcare. I do have close to 40 years on Wall Street and I have taught macroeconomics for nearly that long. I started my career as an analyst at Goldman, Sachs and then started my own firm in the 70's. I have spent my life studying the nexus of the capital markets and the macro-economy and have devoted my business career to developing capital market tools when I think they are needed. I became sensitized to the current healthcare crisis in the US about 8 years ago and recognized that we needed to find a way to invest in the innovations that might alleviate the crisis. Thus began a journey that led me to create HealthShares. It may appear that we have burst on the scene, but this has been a long slog. The press may have have its fun calling me stupid, but I can assure all that a great deal of effort and thought went into the creation of this product. ReplyInteractive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
Jeff-I caught a portion of your presentation at the World Series of ETFs in Miami a few weeks ago. Nice Job. It's apparent you're either educated in the medical area or have some experience in the health care arena. Would you mind sharing a little more about your background? It's refreshing to see a CEO with the in-depth knowledge and enthusiasm in the products offered.
Not a bad week for performance and fund flow for HealthShares funds either.
Thank you,
Tom Lydon
ETFtrends.com Reply
Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
The expense ratio for HealthShares Therapeutic ETFs is 75 basis points. Our European Drugs ETF has a 95 basis point expense cap. Although 75 bps is higher than many other ETFs, it is roughly equivalent to the expense load of other specialized products.WTFs, like other index funds in general, generate fewer capital gains due to low turnover of the securities in the portfolio. Generally, ETFs only sell securities to reflect changes in their benchmark index.
Investors in mutual funds may incur significant tax expense when the fund sees redemptions from shareholders. Because ETFs are exchange-traded, selling shareholders sell to other investors in the secondary market. In addition, since ETFs have a creation/redemption facility that allows actual securities, rather than cash, to be distributed to Authorized Participants, there is no realization of capital gain to be distributed to shareholders. Of course, liquidating an ETF position will generate capital gains or losses for the shareholder. Reply
Jackson
Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
FYI for readers:ProFunds provides inverse ETFs (ETFs that provide the opposite performance to an index, so if the index rises the ETF falls -- a short bet), leveraged ETFs (ETFs that provide twice the performance of an index, so if the index rises by 1% the ETF rises by 2%), and short leveraged ETFs (if the index rises by 1%, the ETF falls by 2% -- a strong short bet). The ProFunds family includes inverse and leveraged ETFs covering the main indexes, growth and value, and individual sectors.
You can find articles on the ProFunds ETFs here. Reply
Interactive Q&A: Jeffrey L. Feldman, Creator of HealthShares and Founder and Chairman of XShares Group LLC [view article]
I cannot comment about carbon credits at this time.As to State Shares, I believe many investors will be interested in these securities.
I have a hard time understanding why investors want to put significant assets into emerging markets. Peter Lynch has always said, "invest in what you know." Investing in emerging markets is investing in what you know....nothing about. But investors are seeking to isolate asset classes.
Personally, I'd rather isolate California and invest there as opposed to Turkey or Malaysia. Maybe that's just me.
Your conjecture about state governments is correct. Reply